SFB 1066/2: “Therapy of Metastatic Melanoma by Addressing Tolerance Inducing M2-Macrophages with therapeutic Nanoparticles”.
Laufzeit: 01.01.2017 - 31.12.2021
imported
Kurzfassung
SFB 1066/2: “Therapy of Metastatic Melanoma by Addressing Tolerance Inducing M2-Macrophages with therapeutic Nanoparticles”.
